<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Section 253: Advanced Optogenetics and Chemogenetics for Circuit Manipulation in CBS/PSP</th>
</tr>
<tr>
<td class="label">Opsin Type</td>
<td>Wavelength</td>
</tr>
<tr>
<td class="label">ChR2 (wild-type)</td>
<td>470 nm (blue)</td>
</tr>
<tr>
<td class="label">ChR2(H134R)</td>
<td>470 nm</td>
</tr>
<tr>
<td class="label">Chronos</td>
<td>470 nm</td>
</tr>
<tr>
<td class="label">ChRmine</td>
<td>600 nm (red)</td>
</tr>
<tr>
<td class="label">C1V1</td>
<td>560 nm</td>
</tr>
<tr>
<td class="label">NpHR3.0</td>
<td>580 nm (yellow)</td>
</tr>
<tr>
<td class="label">ArchT</td>
<td>565 nm</td>
</tr>
<tr>
<td class="label">GtACR2</td>
<td>470 nm</td>
</tr>
<tr>
<td class="label">Receptor</td>
<td>Signaling Pathway</td>
</tr>
<tr>
<td class="label">hM4D(Gi)</td>
<td>Gi/o → ↓cAMP</td>
</tr>
<tr>
<td class="label">hM3D(Gq)</td>
<td>Gq → ↑PLC, Ca2+</td>
</tr>
<tr>
<td class="label">hM3D(Gs)</td>
<td>Gs → ↑cAMP</td>
</tr>
<tr>
<td class="label">hM4D(Gi)-mCherry</td>
<td>Gi (fluorescent)</td>
</tr>
</table>
<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Section 253: Advanced Optogenetics and Chemogenetics for Circuit Manipulation in CBS/PSP</th>
</tr>
<tr>
<td class="label">Opsin Type</td>
<td>Wavelength</td>
</tr>
<tr>
<td class="label">ChR2 (wild-type)</td>
<td>470 nm (blue)</td>
</tr>
<tr>
<td class="label">ChR2(H134R)</td>
<td>470 nm</td>
</tr>
<tr>
<td class="label">Chronos</td>
<td>470 nm</td>
</tr>
<tr>
<td class="label">ChRmine</td>
<td>600 nm (red)</td>
</tr>
<tr>
<td class="label">C1V1</td>
<td>560 nm</td>
</tr>
<tr>
<td class="label">NpHR3.0</td>
<td>580 nm (yellow)</td>
</tr>
<tr>
<td class="label">ArchT</td>
<td>565 nm</td>
</tr>
<tr>
<td class="label">GtACR2</td>
<td>470 nm</td>
</tr>
<tr>
<td class="label">Receptor</td>
<td>Signaling Pathway</td>
</tr>
<tr>
<td class="label">hM4D(Gi)</td>
<td>Gi/o → ↓cAMP</td>
</tr>
<tr>
<td class="label">hM3D(Gq)</td>
<td>Gq → ↑PLC, Ca2+</td>
</tr>
<tr>
<td class="label">hM3D(Gs)</td>
<td>Gs → ↑cAMP</td>
</tr>
<tr>
<td class="label">hM4D(Gi)-mCherry</td>
<td>Gi (fluorescent)</td>
</tr>
</table>
This section provides comprehensive coverage of advanced optogenetics and chemogenetics (DREADDs - Designer Receptors Exclusively Activated by Designer Drugs) technologies for precise neural circuit manipulation in corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP). These cutting-edge neuromodulation approaches offer cell-type-specific, temporally precise control over neural circuits that degenerate in 4R-tauopathies, potentially providing therapeutic benefits for both motor and cognitive symptoms.
Optogenetics and chemogenetics represent a paradigm shift from traditional pharmacological and electrical neuromodulation approaches. Unlike dopaminergic medications that affect the entire brain or DBS that stimulates broad brain regions, these technologies enable circuit-specific manipulation based on cell-type expression patterns. This specificity is particularly relevant for CBS/PSP, where distinct neuronal populations in the basal ganglia, cortex, and brainstem exhibit differential vulnerability to 4R-tau pathology.
Building upon the foundational optogenetics and chemogenetics technology pages at [Optogenetics Technology](/technologies/optogenetics) and [Chemogenetics (DREADDs) Technology](/technologies/chemogenetics), this section focuses on therapeutic applications specific to CBS/PSP pathophysiology, current research status, and clinical translation considerations for this patient population.
Related sections include [Section 129: Multimodal Neuromodulation](/therapeutics/section-129-multimodal-neuromodulation-cbs-psp), which covers combined stimulation approaches, [Section 145: Advanced Ion Channel Modulation](/therapeutics/section-145-advanced-ion-channel-modulation-cbs-psp), which addresses complementary molecular targets, and [Section 241: Advanced Gene Therapy/CRISPR](/therapeutics/section-241-advanced-gene-therapy-crispr-approaches-cbs-psp), which discusses viral vector delivery platforms that enable optogenetic/chemogenetic expression.
Optogenetics offers several advantages for understanding and treating CBS/PSP:
Circuit-Specific Targeting: The basal ganglia-thalamocortical circuit dysfunction in CBS/PSP involves specific neuronal populations - particularly the indirect pathway medium spiny neurons (MSNs) expressing D2 receptors, hyperdirect pathway cortical inputs, and the subthalamic nucleus (STN). Opsin expression can be restricted to these populations using cell-type-specific promoters (e.g., CaMKIIa for excitatory neurons, GAD2 for GABAergic neurons, or Cre-driver lines for striatal MSNs)[@gradinaru2009].
Temporal Precision: Millisecond-scale optical control enables precise timing of neural activity patterns that may be critical for normalizing pathological oscillatory activity in the beta frequency band (13-30 Hz), which is elevated in both Parkinson's disease and likely contributes to motor symptoms in CBS/PSP[@kravitz2010].
Bidirectional Control: Both excitatory (channelrhodopsin-2, ChR2) and inhibitory (halorhodopsin, NpHR; archaerhodopsin, ArchT) opsins enable both activation of underactive circuits (direct pathway) and suppression of overactive circuits (indirect pathway)[@boyden2005].
Mechanistic Insight: Optogenetics provides causal evidence linking specific circuit activity to behavioral phenotypes, enabling identification of optimal stimulation targets and parameters.
For CBS/PSP research and future therapy, red-shifted opsins like ChRmine offer advantages for potential transcranial or fiberless approaches, while fast kinetics variants enable precise pattern generation.
The basal ganglia circuit abnormalities in CBS/PSP differ from Parkinson's disease due to cortical and brainstem involvement:
Subthalamic Nucleus (STN): The STN is hyperactive in both PD and CBS/PSP, contributing to excessive inhibition of the thalamocortical motor pathway. Optogenetic inhibition of STN excitatory outputs to the globus pallidus interna (GPi) could reduce pathological output[@fischer2020].
Striatum: Both direct (D1-expressing) and indirect (D2-expressing) pathway MSNs are affected. Selective activation of D1-MSNs or inhibition of D2-MSNs could theoretically restore motor initiation[@kravitz2010].
Globus Pallidus externa (GPe): GPe activity is abnormal in parkinsonian states. Optogenetic manipulation of GPe neurons expressing parvalbumin or arkypallidal neurons may normalize network oscillations.
Pedunculopontine Nucleus (PPN): The PPN is critical for gait and postural control - severely affected in PSP. Optogenetic stimulation of cholinergic PPN neurons may improve axial symptoms.
Motor Cortex (M1): In CBS, cortical degeneration contributes to apraxia and alien limb phenomena. Optogenetic activation of remaining corticospinal neurons may enhance motor output[@mittmann2015].
Premotor/Supplementary Motor Area: These regions are involved in movement planning and may compensate for basal ganglia dysfunction.
Superior Colliculus: The intermediate layers generate saccades and are affected in PSP vertical gaze palsy. Optogenetic manipulation could potentially improve eye movement control.
Rostral Interstitial MLF: Controls vertical saccades - directly affected by 4R-tau pathology in PSP.
Viral Vectors: Recombinant AAV vectors (serotypes AAV2/9, AAV1, AAV-PHP.B) deliver opsin genes to target neurons. For basal ganglia targeting, stereotactic injection into striatum, STN, or GPi enables regional expression.
Fiber Optic Implants: Flexible fiber optics (200-400 μm diameter) deliver light to target regions. Chronic implants enable long-term studies and potential therapy.
Wireless Optoelectronic Devices: Emerging wireless LED systems eliminate external fiber connections, improving practicality for chronic applications.
Transcranial Approaches: Emerging red-shifted opsins (ChRmine) and transcranial optogenetics approaches may enable non-invasive delivery in the future.
Chemogenetics uses genetically engineered G-protein-coupled receptors that are only activated by synthetic ligands (designer drugs). The most established system is DREADDs (Designer Receptors Exclusively Activated by Designer Drugs)[@armbruster2007][@sternson2014].
Advantages over Optogenetics:
Deschloroclozapine (DCZ): The preferred ligand for human translation. High potency (10-100x higher than CNO), better brain penetration, and lower off-target effects. Dose: 0.01-0.1 mg/kg IP or 0.1-1.0 mg/kg oral[@roth2016].
Clozapine: At low doses (0.1-0.5 mg/kg), clozapine itself can activate hM3D(Gq) and hM4D(Gi), offering a clinically available option.
Clozapine-N-oxide (CNO): Traditional DREADD ligand, but limited brain penetration and back-metabolism to clozapine have reduced its utility.
Striatal D2-MSNs: Inhibition via hM4D(Gi) could reduce excessive indirect pathway activity contributing to bradykinesia and rigidity.
Subthalamic Nucleus: Inhibition of overactive STN neurons may improve motor symptoms similar to traditional DBS but with less invasive hardware.
GPi/SNr Output Neurons: Modulation of the thalamocortical drive could normalize motor output.
Prefrontal Cortex: In CBS, cognitive deficits (executive dysfunction, working memory impairment) involve prefrontal circuit dysfunction. hM3D(Gq) activation could enhance prefrontal excitability.
Anterior Cingulate Cortex: Involved in apathy, a common symptom in PSP. DREADD modulation may improve motivation.
Amygdala/Cingulate Circuit: May address emotional blunting and depression in CBS/PSP.
Pedunculopontine Nucleus (PPN): Cholinergic neuron modulation may improve gait freezing and postural instability in PSP[@snyder2023].
Pontine Reticular Formation: Involved in sleep-wake regulation - affected in CBS/PSP sleep disorders.
Superior Colliculus: Potential target for gaze palsy in PSP - experimental approach.
PSEMs represent an emerging chemogenetic system with potentially improved specificity. PSAMs (Pharmacologically Selective Actuator Modules) are ligand-gated ion channels that respond to pharmacologically selective agonists (PSEMs)[@elizabeth2023].
Advantages:
Preclinical (Animal Models):
Delivery: Requires neurosurgical vector injection into target brain regions - invasive procedure with risks.
Expression Specificity: Achieving cell-type-specific expression in human brain is challenging. Promoter systems may not translate from mouse to human.
Safety Concerns:
Levodopa Interaction: Current levodopa therapy primarily affects dopaminergic terminals. Optogenetic/chemogenetic approaches would target downstream circuits - potentially complementary rather than redundant. No known direct interactions.
Rasagiline: MAO-B inhibitor may have neuroprotective effects - compatible with any circuit manipulation strategy.
Potential Synergies:
50-year-old male with CBS/PSP differential, alpha-synuclein negative (likely 4R-tauopathy), on levodopa and rasagiline.
Clinical Relevance: While optogenetics and chemogenetics are not yet clinically available, they represent important emerging therapies that this patient may benefit from in the future. Understanding the underlying circuit dysfunction enables better interpretation of current treatments and prepares for clinical trials.
NET Assessment: 15/60 (25%) - low current clinical applicability but high future potential as technology matures.
Anterior Olfactory Nucleus (Ao) Opsins: Light-gated anion channels that provide inhibition without cellular damage.
Meganopsins: Engineered opsins with improved kinetics and trafficking.
Chemogenetics + Optogenetics Hybrid: Combining DREADDs with optogenetic tools for dual control.
Closed-Loop Systems: Adaptive neuromodulation responding to real-time neural recordings.